Michele Baccarani
About
In The Last Decade
Michele Baccarani
696 papers receiving 28.2k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Hematology 20.3k
- Genetics 14.6k
- Rheumatology 8.1k
- Oncology 5.9k
- Molecular Biology 4.9k
Countries citing papers authored by Michele Baccarani
This map shows the geographic impact of Michele Baccarani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Baccarani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Baccarani more than expected).
Fields of papers citing papers by Michele Baccarani
This network shows the impact of papers produced by Michele Baccarani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Baccarani. The network helps show where Michele Baccarani may publish in the future.
Co-authorship network of co-authors of Michele Baccarani
This figure shows the co-authorship network connecting the top 25 collaborators of Michele Baccarani. A scholar is included among the top collaborators of Michele Baccarani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Baccarani. Michele Baccarani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 16 | |
| 2 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial breakdown → | 621 |
| 3 | 18 | |
| 4 | 38 | |
| 5 | 58 | |
| 6 | 219 | |
| 7 | Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibi | 3 |
| 8 | GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION | 2 |
| 9 | 57 | |
| 10 | 182 | |
| 11 | Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. | 11 |
| 12 | 1 | |
| 13 | First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. | 146 |
| 14 | The quantitaive assessment of WT1 gene expression as a method to predict response to STI571 therapy in CML patients | 1 |
| 15 | Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. | 36 |
| 16 | Real-time quantification of different types of BcrAbl transcript in chronic myeloid leukemia | 16 |
| 17 | P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. | 30 |
| 18 | Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies. | 2 |
| 19 | Effect of early splenectomy and cyclic acute leukemia-like chemotherapy on the course of chronic myeloid leukemia. | 6 |
| 20 | The relevance of extramedullary hemopoiesis to the staging of chronic myeloid leukemia. | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.